Comparative Safety of Sodium-Glucose Cotransporter 2 Inhibitors Versus Dipeptidyl Peptidase 4 Inhibitors and Sulfonylureas on the Risk of Diabetic Ketoacidosis > 2022

본문 바로가기

접속자집계

오늘
1,646
전체
2,137,840
TEL:02-3789-7891
사이트 내 전체검색

Home >
2022

Comparative Safety of Sodium-Glucose Cotransporter 2 Inhibitors Versus…

작성자 채식영양
작성일 22-01-01 00:00 | 조회 0 | 댓글 0

본문

GK. Dawwas, JH. Flory, S. Hennessy, CE. Leonard and JD. Lewis (2022). Comparative Safety of Sodium-Glucose Cotransporter 2 Inhibitors Versus Dipeptidyl Peptidase 4 Inhibitors and Sulfonylureas on the Risk of Diabetic Ketoacidosis. Diabetes care, 45(4), 919-927. https://doi.org/10.2337/dc21-2177

PubMed 35147696


[Abstract]
OBJECTIVE: To assess the association of sodium-glucose cotransporter 2 (SGLT2) inhibitors with diabetic ketoacidosis compared with dipeptidyl peptidase 4 (DPP-4) inhibitors and sulfonylureas in patients with type 2 diabetes.

RESEARCH DESIGN AND METHODS: We conducted a new-user active comparator cohort study to examine two pairwise comparisons: 1) SGLT2 inhibitors versus DPP-4 inhibitors and 2) SGLT2 inhibitors versus sulfonylureas. The main outcome was diabetic ketoacidosis present on hospital admission. We adjusted for confounders through propensity score matching. We used Cox proportional hazards regression with a robust variance estimator to estimate hazard ratios (HRs) and corresponding 95% CIs while adjusting for calendar time.

RESULTS: In cohort 1 (n = 85,125 for SGLT2 inhibitors and n = 85,125 for DPP-4 inhibitors), the incidence rates of diabetic ketoacidosis per 1,000 person-years were 6.0 and 4.3 for SGLT2 inhibitors and DPP4 inhibitors, respectively. In cohort 2 (n = 72,436 for SGLT2 inhibitors and n = 72,436 for sulfonylureas), the incidence rates of diabetic ketoacidosis per 1,000 person-years were 6.3 and 4.5 for SGLT2 inhibitors and sulfonylureas, respectively. In Cox proportional hazards regression models, the use of SGLT2 inhibitors was associated with a higher rate of diabetic ketoacidosis compared with DPP-4 inhibitors (adjusted HR [aHR] 1.63; 95% CI 1.36, 1.96) and sulfonylureas (aHR 1.56; 95% CI 1.30, 1.87).

CONCLUSIONS: In this comparative safety study using real-world data, patients with type 2 diabetes who were newly prescribed SGLT2 inhibitors had a higher rate of diabetic ketoacidosis compared with DPP-4 inhibitors and sulfonylureas. Clinicians should be vigilant about this association.

0
  • 페이스북으로 보내기
  • 트위터로 보내기
  • 구글플러스로 보내기

댓글목록 0

등록된 댓글이 없습니다.

Total 381
2022 목록
번호 제목 글쓴이 날짜 조회 추천
351 텍스트 Supraventricular tachycardia associated with severe diabetic… 링크 채식영양 01-01 1 0
350 텍스트 "The Bitter Truth of Sugar"-Euglycemic Diabetic Ketoacidosis… 링크 채식영양 01-01 1 0
349 텍스트 Severe Rhabdomyolysis and Acute Renal Failure Treated by Con… 링크 채식영양 01-01 0 0
348 텍스트 COVID-19-Related Multisystem Inflammatory Syndrome in Childr… 링크 채식영양 01-01 1 0
347 텍스트 Sudden Death in Diabetic Ketoacidosis Complicated by Sickle … 링크 채식영양 01-01 1 0
346 텍스트 Diabetic ketoacidosis with severe hypokalemia and persistent… 링크 채식영양 01-01 1 0
열람중 텍스트 Comparative Safety of Sodium-Glucose Cotransporter 2 Inhibit… 링크 채식영양 01-01 1 0
344 텍스트 Diabetic Ketoacidosis With Acute Metabolic Pancreatitis: Two… 링크 채식영양 01-01 1 0
343 텍스트 Breath Analysis for the In Vivo Detection of Diabetic Ketoac… 링크 채식영양 01-01 0 0
342 텍스트 Evaluating diabetic ketoacidosis via a MOF sensor for fluore… 링크 채식영양 01-01 1 0
341 텍스트 Diabetic Ketoacidosis After Sodium-Glucose Cotransporter Inh… 링크 채식영양 01-01 1 0
340 텍스트 Diabetic ketoacidosis shortly after COVID-19 vaccination in … 링크 채식영양 01-01 1 0
339 텍스트 Diabetic ketoacidosis and acute pancreatitis in a patient wi… 링크 채식영양 01-01 1 0
338 텍스트 Sodium-glucose cotransporter-2 inhibitors induced euglycemic… 링크 채식영양 01-01 1 0
337 텍스트 Hyperosmolar Therapy for Diabetic Hyperosmolar Ketoacidosis 링크 채식영양 01-01 1 0
게시물 검색

한국채식정보. 대표:이광조ㅣsoypaper@hanmail.netㅣ대표전화: 02-3789-7891ㅣ서울시 용산구 갈월동 56-5. 일심빌딩 203호